Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib for RDEB-associated advanced or metastatic squamous cell carcinoma
2024-518846-25-00Phase 2Completed
- Sponsor
- Salzburger Landeskliniken
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in cutaneous squamous cell carcinoma (cSCC) and Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Salzburger Landeskliniken. Primary endpoints: Objective response rate and Safety and tolerability. Started Dec 2024; status: completed.
02
Drugs
rigosertib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on 2024-518846-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518846-25-00.